LEXINGTON, Massachusetts & SYDNEY, Australia – 19 November 2014 – GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that Michael Dale, president and chief executive officer, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference taking place in New York City. Mr. Dale is scheduled to give a presentation and company overview on Wednesday, December 3, 2014, at 3 p.m. ET.
A live audio webcast of this presentation can be accessed by visiting http://investor.gidynamics.com. A replay of the webcast will be available on the company’s website following the live presentation.
About GI Dynamics
GI Dynamics, Inc. (ASX: GID) is the developer and marketer of EndoBarrier®, a breakthrough device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.